SCHEMBL4375853

SCHEMBL4375853

Cc1cccc(C)c1-n1c(C)cc(O)c(Br)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.48
ANPEP P15144 1/20 0.39
DPP4 P27487 1/20 0.39
ALDH1A1 P00352 4/20 0.38
HPGD P15428 1/20 0.38
TRPA1 O75762 2/20 0.37
ATM Q13315 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.35
MAPT P10636 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
ALOX12 P18054 1/20 0.35
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DAO P14920 2/20 0.34
DDO Q99489 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377591 0.87 APLNR (0.48) MAPK14ALDH1A1HPGDATML3MBTL1
SCHEMBL4384354 0.84 MAPK14 (0.53) MAPK14L3MBTL1
SCHEMBL4384792 0.84 MAPK14 (0.56) MAPK14
SCHEMBL4381208 0.75 ANPEP (0.45) MAPK14ANPEPDPP4ALDH1A1HPGD
SCHEMBL31381798 0.72 MAPK14 (0.36) MAPK14L3MBTL1MAPTKDM4E
SCHEMBL12798301 0.71 MAPK14 (0.44) MAPK14ALDH1A1POLBL3MBTL1TDP1
SCHEMBL2706985 0.71 ALDH1A1 (0.53) MAPK14ALDH1A1MEN1KMT2APOLB
SCHEMBL27758375 0.70 MYC (0.38) MAPK14ALDH1A1MEN1KMT2APOLB
SCHEMBL6498931 0.70 L3MBTL1 (0.44) MAPK14ALDH1A1HPGDTRPA1POLB
SCHEMBL4386875 0.69 MAPK14 (0.47) MAPK14L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPK14 41/4885ANPEP 4541/4885DPP4 4201/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPK14 53/4885ANPEP 4342/4885DPP4 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.